Magnus Blixt is currently CFO of CellaVision AB, a global medical technology company listed on the Nasdaq Nordic Mid Cap list. Blixt has held that role since 2013 and has supported a profitable growth agenda generated by a scalable indirect business model. He has extensive experience developing small and medium-sized companies focusing on business performance and process improvements. He previously held positions in the SKF Group as Business Demand Manager and Operations Manager, and as CFO of an SKF Sealing Solutions company in the United States he supported the integration of that company into the broader SKF organization. He has an MBA from Lund University.

“I appreciate the entrepreneurial spirit of Dignitana and I see many similarities in this company compared to where CellaVision was when I joined that company,” said Magnus Blixt. “Dignitana is a growing company with tremendous potential – it has global reach, an excellent product, and a solid foundation. I am excited about the opportunity and look forward to continuing the good work of the company to improve well-being and the lives of cancer patients.”

“The strategic expansion of the company is our top priority,” said Klas Arildsson, Chairman of the Board, Dignitana AB. “We are well-positioned to take advantage of the opportunities before us in the critical US market and around the globe, and the financial and operational experience that Magnus Blixt brings will be a tremendous asset to the Company.”

To support Dignitana’s commitment to global expansion the CEO position will be based at the Company headquarters in Lund along with other key positions.